Vafadar Sam
Sam Vafadar practices in the Department of Thoracic Medical Oncology at H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fla. The author has disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2017 Jun;30(6):48-50. doi: 10.1097/01.JAA.0000515557.14603.c7.
Lung cancer is the third most common cancer in the United States and the top cause of cancer-related mortality in men and women. Despite advances in chemotherapy, molecular therapies, and CT screening, overall survival remains dismal. Additional options and a new treatment paradigm are needed. This article focuses on immunotherapy, a promising new approach targeted at the PD-1 inhibition pathway.
肺癌是美国第三大常见癌症，也是男性和女性癌症相关死亡的首要原因。尽管在化疗、分子疗法和CT筛查方面取得了进展，但总体生存率仍然很低。需要更多的选择和新的治疗模式。本文重点关注免疫疗法，这是一种针对PD-1抑制途径的有前景的新方法。
